These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

965 related articles for article (PubMed ID: 25076244)

  • 1. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
    Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
    Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Taiwan hospital-based detection of Lynch syndrome distinguishes 2 types of microsatellite instabilities in colorectal cancers.
    Chang SC; Lin PC; Yang SH; Wang HS; Liang WY; Lin JK
    Surgery; 2010 May; 147(5):720-8. PubMed ID: 20045164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
    Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
    J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer.
    Loughrey MB; Waring PM; Tan A; Trivett M; Kovalenko S; Beshay V; Young MA; McArthur G; Boussioutas A; Dobrovic A
    Fam Cancer; 2007; 6(3):301-10. PubMed ID: 17453358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
    Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
    Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the performance of clinical criteria for predicting mismatch repair gene mutations in Lynch syndrome: a comprehensive analysis of 3,671 families.
    Steinke V; Holzapfel S; Loeffler M; Holinski-Feder E; Morak M; Schackert HK; Görgens H; Pox C; Royer-Pokora B; von Knebel-Doeberitz M; Büttner R; Propping P; Engel C;
    Int J Cancer; 2014 Jul; 135(1):69-77. PubMed ID: 24493211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
    Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY
    Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.
    Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R
    Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for a population specific detection strategy of Lynch syndrome.
    Berginc G; Bracko M; Ravnik-Glavac M; Glavac D
    Fam Cancer; 2009; 8(4):421-9. PubMed ID: 19526325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer.
    Moreira L; Muñoz J; Cuatrecasas M; Quintanilla I; Leoz ML; Carballal S; Ocaña T; López-Cerón M; Pellise M; Castellví-Bel S; Jover R; Andreu M; Carracedo A; Xicola RM; Llor X; Boland CR; Goel A; Castells A; Balaguer F;
    Cancer; 2015 May; 121(9):1395-404. PubMed ID: 25557234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive molecular analysis of mismatch repair gene defects in suspected Lynch syndrome (hereditary nonpolyposis colorectal cancer) cases.
    Mueller J; Gazzoli I; Bandipalliam P; Garber JE; Syngal S; Kolodner RD
    Cancer Res; 2009 Sep; 69(17):7053-61. PubMed ID: 19690142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and molecular detection of inherited colorectal cancers in northeast Italy: a first prospective study of incidence of Lynch syndrome and MUTYH-related colorectal cancer in Italy.
    Urso E; Agostini M; Pucciarelli S; Rugge M; Bertorelle R; Maretto I; Bedin C; D'Angelo E; Mescoli C; Zorzi M; Viel A; Bruttocao G; Ferraro B; Erroi F; Contin P; De Salvo GL; Nitti D
    Tumour Biol; 2012 Jun; 33(3):857-64. PubMed ID: 22278153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.
    Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D
    J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microsatellite instability: an update.
    Yamamoto H; Imai K
    Arch Toxicol; 2015 Jun; 89(6):899-921. PubMed ID: 25701956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bethesda criteria for microsatellite instability testing: impact on the detection of new cases of Lynch syndrome.
    Serrano M; Lage P; Belga S; Filipe B; Francisco I; Rodrigues P; Fonseca R; Chaves P; Claro I; Albuquerque C; Pereira AD
    Fam Cancer; 2012 Dec; 11(4):571-8. PubMed ID: 22776989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MLH1 promoter germline-methylation in selected probands of Chinese hereditary non-polyposis colorectal cancer families.
    Zhou HH; Yan SY; Zhou XY; Du X; Zhang TM; Cai X; Lu YM; Cai SJ; Shi DR
    World J Gastroenterol; 2008 Dec; 14(48):7329-34. PubMed ID: 19109866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome.
    Tresallet C; Brouquet A; Julié C; Beauchet A; Vallot C; Ménégaux F; Mitry E; Radvanyi F; Malafosse R; Rougier P; Nordlinger B; Laurent-Puig P; Boileau C; Emile JF; Muti C; Penna C; Hofmann-Radvanyi H
    Int J Cancer; 2012 Mar; 130(6):1367-77. PubMed ID: 21520036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification.
    Parsons MT; Buchanan DD; Thompson B; Young JP; Spurdle AB
    J Med Genet; 2012 Mar; 49(3):151-7. PubMed ID: 22368298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations.
    Haraldsdottir S; Hampel H; Tomsic J; Frankel WL; Pearlman R; de la Chapelle A; Pritchard CC
    Gastroenterology; 2014 Dec; 147(6):1308-1316.e1. PubMed ID: 25194673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.